Rep. Laura Friedman Shares of Abbott Laboratories (NYSE:ABT)

Representative Laura Friedman (Democratic-California) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on April 17th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on March 24th. The trade occurred in the Representative’s “FIDELITY BROKERAGE SERVICES, LLC” account.

Abbott Laboratories Trading Down 0.8%

NYSE:ABT opened at $96.06 on Tuesday. The stock has a market cap of $167.30 billion, a price-to-earnings ratio of 26.91, a PEG ratio of 1.58 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a 1 year low of $93.92 and a 1 year high of $139.06. The business has a fifty day moving average of $107.59 and a 200-day moving average of $118.29.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The company’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.53 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.6%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Institutional Investors Weigh In On Abbott Laboratories

Large investors have recently made changes to their positions in the company. Carr Financial Group Corp boosted its holdings in Abbott Laboratories by 2.0% in the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after purchasing an additional 76 shares in the last quarter. Gemmer Asset Management LLC raised its holdings in Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after buying an additional 78 shares in the last quarter. Global Financial Private Client LLC lifted its position in shares of Abbott Laboratories by 3.3% in the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after buying an additional 79 shares during the last quarter. Citizens & Northern Corp boosted its stake in shares of Abbott Laboratories by 0.4% during the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after acquiring an additional 79 shares in the last quarter. Finally, American National Bank of Texas boosted its stake in shares of Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after acquiring an additional 79 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group dropped their price target on shares of Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Mizuho dropped their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday. JPMorgan Chase & Co. cut their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday. Leerink Partners decreased their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Finally, Argus dropped their price target on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $120.95.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New long‑term diagnostics data and an AACR award for Abbott’s CancerGuard program reinforce its multi‑cancer early‑detection strategy, strengthening the company’s growth story in diagnostics. Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story
• Positive Sentiment: Barclays maintained an Overweight rating with a $143 target (slightly trimmed from $144), signaling institutional conviction that shares offer meaningful upside versus current levels. Barclays Overweight / PT $143
• Positive Sentiment: Several retail/coverage pieces are flagging ABT as a buy on the pullback, highlighting its diversified healthcare franchise and positioning the sell‑off as a potential long‑term buying opportunity. Market Crash: 2 Healthcare Stocks Worth Loading Up on at a Discount
• Neutral Sentiment: Market commentary (247WallStreet and others) frames today’s lower price as a possible entry point for patient investors but stresses that suitability depends on time horizon and tolerance for near‑term uncertainty. Has the Abbott Laboratories Sell-Off Finally Created an Entry Point?
• Negative Sentiment: Q1 results: adjusted EPS and revenue beat estimates, but management cut full‑year guidance citing a mild flu season and acquisition costs. That guidance cut triggered a sharp post‑earnings sell‑off and spurred social‑media debate — a near‑term catalyst for continued volatility. Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Guidance Cut
• Negative Sentiment: A broad set of sell‑side firms trimmed price targets in the last 24 hours (examples include Mizuho, Piper, JPMorgan, Wells Fargo, Oppenheimer and others), reflecting reduced near‑term visibility and weighing on sentiment despite some buy ratings remaining. Oppenheimer Cuts Abbott Laboratories Price Target

Insider Buying and Selling

In related news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.

About Representative Friedman

Laura Friedman (Democratic Party) is a member of the U.S. House, representing California’s 30th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Friedman (Democratic Party) is running for re-election to the U.S. House to represent California’s 30th Congressional District. She declared candidacy for the 2026 election.

Laura Friedman was born in New York and lives in Glendale, California. Friedman earned a B.A. from the University of Rochester, New York, in 1988. Her career experience includes working as a producer and head of development in the entertainment industry and as a small business owner selling antiques and decorative arts. Friedman served on the board of directors of the Metropolitan Water District of Southern California, as past president of the Independent Cities Association, as a board member of the Southern California Association of Governments, and on the Glendale Design Review Board. She was elected to the Glendale City Council in 2009 and re-elected in 2013. She served as mayor of Glendale from 2011 to 2012.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.